Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.

Academic Article


  • Data from 1330 human immunodeficiency virus type 1 (HIV-1)-infected patients enrolled in seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of treatment-mediated reductions in plasma HIV-1 RNA levels. The risk of a new AIDS-defining event or death was reduced proportionally to the magnitude of the reduction of the HIV-1 RNA level during the first 6 months of therapy. Pretherapy HIV-1 RNA levels were prognostic independently of on-therapy levels. In addition, the reduction in risk associated with any given reduction of the level of HIV-1 RNA did not vary by pretherapy level. Having either a reduction in HIV-1 RNA level or an increase in CD4+ lymphocyte count, or both, was associated with a delay in clinical disease progression. This indicates that patient prognosis should be assessed using both HIV-1 RNA and CD4+ lymphocyte responses to therapy.
  • Published In


  • Acquired Immunodeficiency Syndrome, Adult, Anti-HIV Agents, Antiviral Agents, CD4 Lymphocyte Count, Disease Progression, Double-Blind Method, Drug Monitoring, Female, HIV Infections, HIV-1, Humans, Male, Plasma, Prognosis, RNA, Viral, Retrospective Studies, Risk
  • Author List

  • Marschner IC; Collier AC; Coombs RW; D'Aquila RT; DeGruttola V; Fischl MA; Hammer SM; Hughes MD; Johnson VA; Katzenstein DA
  • Start Page

  • 40
  • End Page

  • 47
  • Volume

  • 177
  • Issue

  • 1